ASX:FTT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Factor Therapeutics Limited operates as a clinical stage biotechnology company. More Details


Snowflake Analysis

Flawless balance sheet and good value.

Share Price & News

How has Factor Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FTT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

FTT

-1.2%

AU Biotechs

-2.4%

AU Market


1 Year Return

42.9%

FTT

14.2%

AU Biotechs

-8.3%

AU Market

Return vs Industry: FTT exceeded the Australian Biotechs industry which returned 19.8% over the past year.

Return vs Market: FTT exceeded the Australian Market which returned -6.3% over the past year.


Shareholder returns

FTTIndustryMarket
7 Day0%-1.2%-2.4%
30 Day0%-1.4%1.8%
90 Day-16.7%6.6%1.7%
1 Year42.9%42.9%15.3%14.2%-5.0%-8.3%
3 Year-91.0%-91.1%115.6%108.5%14.6%-0.08%
5 Year-89.9%-90.4%215.8%197.2%41.6%12.1%

Price Volatility Vs. Market

How volatile is Factor Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Factor Therapeutics undervalued compared to its fair value and its price relative to the market?

18.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: FTT (A$0.01) is trading below our estimate of fair value (A$0.01)

Significantly Below Fair Value: FTT is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: FTT is good value based on its PE Ratio (19.3x) compared to the XX Biotechs industry average (54.2x).

PE vs Market: FTT is good value based on its PE Ratio (19.3x) compared to the Australian market (20.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FTT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FTT is good value based on its PB Ratio (1.5x) compared to the AU Biotechs industry average (6.2x).


Next Steps

Future Growth

How is Factor Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Factor Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Factor Therapeutics performed over the past 5 years?

33.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FTT has high quality earnings.

Growing Profit Margin: FTT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: FTT has become profitable over the past 5 years, growing earnings by 33.4% per year.

Accelerating Growth: FTT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: FTT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).


Return on Equity

High ROE: FTT's Return on Equity (7.7%) is considered low.


Next Steps

Financial Health

How is Factor Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: FTT's short term assets (A$3.6M) exceed its short term liabilities (A$42.8K).

Long Term Liabilities: FTT has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: FTT is debt free.

Reducing Debt: FTT has not had any debt for past 5 years.

Debt Coverage: FTT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: FTT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Factor Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FTT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FTT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FTT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FTT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FTT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average board tenure


CEO

Factor Therapeutics has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Robert Kirsner
Member of Medical Advisory Board4.17yrsno datano data
John Michailidis
Independent Non Executive Director3.67yrsAU$21.40k0.051%
A$ 2.6k
Keith Harding
Member of Medical Advisory Board4.17yrsno datano data
David Brookes
Chairman0.25yrAU$19.16k1.23%
A$ 64.0k
David Margolis
Member of Medical Advisory Board4.17yrsno datano data
Christian Behrenbruch
Independent Non Executive Director5yrsAU$21.60k0.31%
A$ 16.3k
Ronald Shannon
Member of Medical Advisory Boardno datano datano data

4.2yrs

Average Tenure

Experienced Board: FTT's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Factor Therapeutics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Factor Therapeutics Limited
  • Ticker: FTT
  • Exchange: ASX
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$5.214m
  • Shares outstanding: 1.04b
  • Website: https://www.factor-therapeutics.com

Location

  • Factor Therapeutics Limited
  • 10 Eagle Street
  • Level 21
  • Brisbane
  • Queensland
  • 4000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FTTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDMar 2004
1TTDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2004
FTTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDMar 2004

Biography

Factor Therapeutics Limited operates as a clinical stage biotechnology company. The company was formerly known as Tissue Therapies Limited and changed its name to Factor Therapeutics Limited in May 2016. F ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/12 10:34
End of Day Share Price2020/07/15 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.